ArticleDiscover oncology2025
The influence of ferroptosis-associated gene HSPA5 on the prognosis and immune evasion of lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A new era of precision diagnosis and treatment for lung cancer: artificial intelligence-driven multimodal data integration and clinical applications.Cell death & disease · 2026Review
- Ferroptosis in diabetic retinopathy: from pathogenic mechanisms to translational prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUtilizing bioinformatics technology, we aim to screen for differentially expressed genes associated with ferroptosis in lung adenocarcinoma, aiming to identify ferroptosis-related genes that significantly impact the prognosis and immune evasion of this malignancy.
methodsRNA-seq data from TCGA and GEO repositories, along with clinical information pertaining to lung adenocarcinoma (LUAD), were compiled and subjected to rigorous analysis to identify differentially expressed genes linked to ferroptosis. Additionally, we examined the prognostic significance of these genes. Concurrently, the correlation between ferroptosis-related genes and immune evasion was scrutinized using the TIDE built-in dataset, resulting in the identification of hub genes. Subsequently, TCGA sequencing data were utilized to delve into the regulatory mechanisms of ferroptosis genes. Finally, to gain further insights, cell experiments were conducted to investigate the alterations in biological functions of LUAD cells following the knockdown of the promising ferroptosis gene, HSPA5.
resultsThe expression of ACSL4 was low in tumor tissues, while DPP4, HSPA5 and HSPB1 were high in tumor tissues. Ferroptosis-related genes HSPA5, GLS2, CDKN1A, FANCD2, SLC7A11, SLC1A5, CARS1, ALOX15, RPL8 associated with prognosis of lung adenocarcinoma. Ferroptosis gene HSPA5 is regulated by transcription factor and ceRNA network to reduce the efficacy of immunotherapy in LUAD. Knockdown of HSPA5 can induce apoptosis of LUAD cells.
conclusionThe ferroptosis-related gene HSPA5 diminishes the effectiveness of LUAD immunotherapy by promoting immune evasion, thus serving as a potential indicator for predicting the therapeutic response. Notably, patients with lower HSPA5 expression tend to have a more favorable prognosis. Our discoveries may contribute significantly to the advancement of personalized treatment strategies and the enhancement of immunotherapy outcomes for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.